AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NYRADA INC-CDI

0.740

+0.0304.23%

Volume:119.61K

Turnover:85.86K

Market Cap:182.85M

PE:-26.97

High:0.740

Open:0.710

Low:0.710

Close:0.710

52wk High:1.435

52wk Low:0.250

Shares:247.09M

Float Shares:102.11M

Volume Ratio:27.47

T/O Rate:0.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.027

EPS(LYR):-0.027

ROE:-99.95%

ROA:-53.59%

PB:19.16

PE(LYR):-26.97

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

ASX Penny Stocks To Watch: 3 Picks Under A$200M Market Cap

Simply Wall St.

Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%

MT Newswires Live

Nyrada Inc-Preliminary Final Report

THOMSON REUTERS

Nyrada Builds Cash Balance in June Quarter With Receipt of R&D Tax Incentive

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/NYR.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NYR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","market":"AU","secType":"STK","nameCN":"NYRADA INC-CDI","latestPrice":0.74,"timestamp":1789344487481,"preClose":0.71,"halted":0,"volume":119606,"delay":0,"changeRate":0.042253521126760604,"nameEN":"NYRADA INC-CDI","floatShares":102113109,"shares":247092830,"eps":-0.02744,"marketStatus":"Trading","change":0.03,"latestTime":"09-14 10:08:38 AEST","open":0.71,"high":0.74,"low":0.71,"amount":85863,"amplitude":0.042254,"askPrice":0.745,"askSize":1421,"bidPrice":0.74,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.02744,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789365600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.71,"openAndCloseTimeList":[[1789344000000,1789365600000]],"volumeRatio":27.47318,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NYR.AU","preClose":0.71,"auctionPrice":0.71,"auctionVolume":6596,"auctionTime":1789334402492,"referenceTime":1789122603091,"auction":1,"marketStatus":"盘前竞价","timestamp":1789334402492}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","floatShares":102113109,"roa":"-53.59%","roe":"-99.95%","lyrEps":-0.02744,"volumeRatio":27.47318,"shares":247092830,"dividePrice":0,"high":0.74,"amplitude":0.042254,"preClose":0.71,"low":0.71,"week52Low":0.25,"pbRate":"19.16","psRate":"90.91","week52High":1.435,"institutionHeld":0,"latestPrice":0.74,"committee":-0.173895,"eps":-0.02744,"divideRate":0,"volume":119606,"delay":0,"ttmEps":-0.02744,"open":0.71,"prevYearClose":1.12,"prevWeekClose":0.71,"prevMonthClose":0.83,"prevQuarterClose":0.45,"fiveDayClose":0.74,"twentyDayClose":0.735,"sixtyDayClose":0.46},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NYR.AU\",params:#limit:5,,,undefined,":[{"date":"2023-07-28","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690502400000,"name":null,"time":"","dateTimestamp":1690466400000,"actualEps":null},{"date":"2023-04-29","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1682726400000,"name":null,"time":"","dateTimestamp":1682690400000,"actualEps":null},{"market":"AU","date":"2022-08-29","symbol":"NYR.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1661695200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NYR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NYR.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662508557","title":"ASX Penny Stocks To Watch: 3 Picks Under A$200M Market Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2662508557","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662508557?lang=en_us&edition=fundamental","pubTime":"2026-08-26 03:02","pubTimestamp":1787684525,"startTime":"0","endTime":"0","summary":"The ASX is poised for a strong start today, buoyed by positive corporate reporting and lower oil prices, even as global markets face mixed signals. For investors interested in exploring beyond the major players, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities. Despite their somewhat outdated name, these stocks can present valuable growth potential when backed by solid financial fundamentals.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-al3/aml3d-shares/news/asx-penny-stocks-to-watch-3-picks-under-a200m-market-cap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-al3/aml3d-shares/news/asx-penny-stocks-to-watch-3-picks-under-a200m-market-cap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7094","BK7088","ALC.AU","AL3.AU","BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661558592","title":"Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661558592","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661558592?lang=en_us&edition=fundamental","pubTime":"2026-08-21 08:54","pubTimestamp":1787273690,"startTime":"0","endTime":"0","summary":"Nyrada  said its Xolatryp drug candidate provided significant protection to cardiac function against progressive doxorubicin-induced cardiotoxicity in a preclinical study, according to a Friday filing with the Australian bourse.Doxorubicin is an anthracycline drug widely used as a first-line treatment for both solid and metastatic tumors, and is considered a \"backbone drug\" in oncology, the company said.Doxorubicin treatment weakened the heart's ability to pump and empty blood effectively, and Xolatryp delivered benefits across four key measures of heart performance that were negatively impacted by doxorubicin, Nyrada said.The magnitude of functional protection was comparable to dexrazoxane, which is the only approved cardioprotective agent, per the filing.Nyrada said it will assess the design and feasibility of a potential phase 1b clinical trial of Xolatryp in the oncology setting.The company's share gained 5% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660845604","title":"Nyrada Inc-Preliminary Final Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2660845604","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660845604?lang=en_us&edition=fundamental","pubTime":"2026-08-18 11:05","pubTimestamp":1787022349,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nTUE6NYCPC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654096125","title":"Nyrada Builds Cash Balance in June Quarter With Receipt of R&D Tax Incentive","url":"https://stock-news.laohu8.com/highlight/detail?id=2654096125","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654096125?lang=en_us&edition=fundamental","pubTime":"2026-07-27 11:23","pubTimestamp":1785122584,"startTime":"0","endTime":"0","summary":"Nyrada  ended the June quarter with a cash balance of about AU$8.4 million, up from AU$6.7 million as of March 31, according to a Monday filing with the Australian bourse.Cash operating outflows for the June quarter totaled about AU$1.7 million, offset by AU$60,000 of interest income and the receipt of a roughly AU$2.5 million research and development tax incentive from the Australian government, per the filing.The company said its phase 2a clinical trial of Xolatryp in heart attack patients remains on track for completion next year, with the final patient expected to be dosed in mid-2027.Nyrada shares fell 1% in recent Monday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NYR.AU\",params:#limit:6,delay:true,,,undefined,":[]}}